• CSBTA Pharmacokinetics in MASH Mice

  2026-08-21

  The reference study integrates plasma pharmacokinetics, tissue distribution, cellular transport, metabolic stability, and regulatory protein expression to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic and hepatic exposure, providing a mechanistic basis for disease-adapted dosing research.

• Pentoxifylline Workflows for Inflammation Research

  2026-08-20

  Pentoxifylline offers a practical way to connect cAMP signaling with cytokine, monocyte, infection, and tissue-inflammation assays. This guide translates reference findings into reproducible cell workflows, dose-selection strategies, cross-domain applications, and troubleshooting steps.

• CD36-Driven Immune Escape in AML

  2026-08-20

  A 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-sensing program that enables acute myeloid leukemia cells to suppress T-cell activity and resist decitabine-based therapy. Its preclinical findings connect oxidized LDL, palmitate, innate immune signaling, and statin-mediated therapeutic sensitization, providing a mechanistic framework for studying lipid-dependent immune escape in AML.

• Indometacin Sodium: Applied Research Workflows

  2026-08-19

  Build more reproducible inflammation assays, pain-signaling studies, and regeneration workflows with Indometacin Sodium. This guide connects concentration selection, pathway-aware controls, solubility management, and troubleshooting to practical bench decisions.

• Minocycline HCl in EV Inflammation Workflows

  2026-08-19

  Minocycline HCl adds a controllable inflammation and cell-survival perturbation layer to scalable extracellular-vesicle assays. This workflow separates producer-cell manufacturing from recipient-cell testing, helping researchers interpret EV bioactivity without confusing antimicrobial, anti-inflammatory, and apoptosis-related effects.

• Eicosapentaenoic Acid: Designing Better Assays

  2026-08-18

  Eicosapentaenoic Acid (EPA) is more than an omega-3 lipid: it is a concentration-sensitive research tool for membrane, oxidation, and vascular assays. This guide connects EPA assay design with new evidence on lipid-driven humoral immunity while clearly separating established findings from testable hypotheses.

• CCK-8s, NOX4, and ANP Secretion in Rat Atria

  2026-08-18

  The reference study identifies a signaling pathway by which sulfated cholecystokinin octapeptide stimulates atrial natriuretic peptide secretion in isolated beating rat atria. Its central finding is that CCK-8s uses a NOX4–PGC-1α–PPARα/PPARγ cascade to connect arachidonic acid signaling, controlled hydrogen peroxide production, atrial mechanics, and cardiac endocrine function.

• Morin: Mitochondrial and Fluorescence Assay Workflows

  2026-08-17

  Morin combines redox, inflammatory, mitochondrial, and metal-chelation use cases in one research reagent. This guide translates its AMPD-focused biology and fluorescent aluminum-ion behavior into practical assay workflows, controls, and troubleshooting strategies without overstating clinical evidence.

• SIRT4, Glutamine Metabolism, and Liver Fibrosis

  2026-08-17

  The reference study identifies SIRT4-controlled glutamine metabolism as a metabolic checkpoint in activated hepatic stellate cells. By combining GDH inhibition with SIRT4 manipulation in cellular and animal models, it shows that limiting glutamate-to-α-ketoglutarate conversion can reduce stellate-cell proliferation and fibrotic progression.

• Tetrahydromagnolol in Translational CB2 Research

  2026-08-16

  Tetrahydromagnolol offers a selective pharmacology framework for connecting peripheral CB2 signaling with anti-inflammatory and analgesic biology. This thought-leadership article translates the TBXA2R–ERM metastasis findings into a disciplined strategy for testing cannabinoid signaling, cytoskeletal remodeling, and disease-relevant phenotypes without overstating an unproven mechanistic link.

• Radioiodinated Balsalazide for UC Imaging in Mice

  2026-08-15

  Sanad and colleagues developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for ulcerative colitis in mice. Their optimized labeling workflow produced a stable radiotracer and high uptake in ulcerated colon, supporting further investigation of balsalazide-based molecular imaging while leaving important questions about receptor specificity and clinical translation unresolved.

• Baicalein: From 12-LOX Biology to Translation

  2026-08-14

  Baicalein offers a pathway-anchored framework for connecting arachidonic acid metabolism, cancer cell proliferation inhibition, apoptosis, and inflammation research. This thought-leadership perspective positions 5,6,7-trihydroxy-2-phenylchromen-4-one as a translational probe—not a presumed neuroprotective therapy—and shows how to test its value without compromising anticancer activity.

• Caffeic Acid Phenethyl Ester in Fyn–NF-κB Models

  2026-08-14

  Caffeic Acid Phenethyl Ester (CAPE) can serve as a mechanistic perturbation tool for separating NF-κB-dependent inflammation from Stat3 signaling in Fyn-driven neurodegeneration models. This article connects zebrafish assay design with CAPE’s validated anti-angiogenic and tumor-invasion research applications while defining the limits of cross-model interpretation.

• A20, Oxidized Self-DNA, and Acute Kidney Injury

  2026-08-13

  The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and establishes A20 as an endogenous brake on this response. Its genetic, pharmacological, and peptide-based experiments connect cGAS–STING signaling to NEK7-dependent NLRP3 pyroptosis, suggesting a mechanistically focused strategy for limiting renal injury.

• Tetrahydromagnolol: Peripheral CB2 Receptor Agonist

  2026-08-13

  Tetrahydromagnolol enables concentration-controlled CB2 activation while also providing a way to interrogate GPR55 antagonism in receptor and cell-based assays. This guide connects cannabinoid signaling workflows with ERM-centered motility studies, emphasizing practical controls, assay selection, and troubleshooting rather than unsupported claims of therapeutic efficacy.

15577 records 1/1039 page Next 12345 下5页 Last page